TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DIVISLAB Stock 12 Month Forecast
There Are No Analyst Ratings for IN:DIVISLAB In The Last 3 Months.
Highest Price Target―
Average Price Target―
Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
DIVISLAB Financial Forecast
DIVISLAB Earnings Forecast
Next quarter’s earnings estimate for DIVISLAB is ₹23.17 with a range of ₹20.57 to ₹24.37. The previous quarter’s EPS was ₹25.97. DIVISLAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.
Next quarter’s earnings estimate for DIVISLAB is ₹23.17 with a range of ₹20.57 to ₹24.37. The previous quarter’s EPS was ₹25.97. DIVISLAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.
DIVISLAB Sales Forecast
Next quarter’s sales forecast for DIVISLAB is ₹26.28B with a range of ₹23.38B to ₹27.44B. The previous quarter’s sales results were ₹27.15B. DIVISLAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.
Next quarter’s sales forecast for DIVISLAB is ₹26.28B with a range of ₹23.38B to ₹27.44B. The previous quarter’s sales results were ₹27.15B. DIVISLAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.
JPMorgan Starts Divi's Laboratories Ltd (DIVI:IN) at OverweightJPMorgan analyst Bansi Desai initiates coverage on Divi's Laboratories Ltd (DIVI:IN) with a Overweight rating and a price target of INR7,800.00.
Jefferies Upgrades Divi's Laboratories Ltd (DIVI:IN) to BuyJefferies analyst Dhawal Khut upgraded Divi's Laboratories Ltd (DIVI:IN) from Hold to Buy with a price target of INR7,150.00 (from INR6,750.00).
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,150 at BofA SecuritiesBofA Securities analyst Neha Manpuria raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,150.00 (from INR6,800.00) while maintaining a Buy rating.
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,750 at CitiCiti analyst Vivek Agrawal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,750.00 (from INR7,050.00) while maintaining a Buy rating.
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,185 at Morgan StanleyMorgan Stanley analyst Binay Singh raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,185.00 (from INR7,141.00) while maintaining a Overweight rating.
JPMorgan Starts Divi's Laboratories Ltd (DIVI:IN) at OverweightJPMorgan analyst Bansi Desai initiates coverage on Divi's Laboratories Ltd (DIVI:IN) with a Overweight rating and a price target of INR7,800.00.
Jefferies Upgrades Divi's Laboratories Ltd (DIVI:IN) to BuyJefferies analyst Dhawal Khut upgraded Divi's Laboratories Ltd (DIVI:IN) from Hold to Buy with a price target of INR7,150.00 (from INR6,750.00).
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,150 at BofA SecuritiesBofA Securities analyst Neha Manpuria raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,150.00 (from INR6,800.00) while maintaining a Buy rating.
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,750 at CitiCiti analyst Vivek Agrawal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,750.00 (from INR7,050.00) while maintaining a Buy rating.
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,185 at Morgan StanleyMorgan Stanley analyst Binay Singh raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,185.00 (from INR7,141.00) while maintaining a Overweight rating.
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.15% per trade.
Copying Kunal Dhamesha's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.40% per trade.
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +11.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DIVISLAB Analyst Recommendation Trends
Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
0
0
0
0
0
Buy
4
4
3
1
0
Hold
1
0
0
0
0
Sell
3
3
1
0
0
Strong Sell
0
0
0
0
0
total
8
7
4
1
0
In the current month, DIVISLAB has received 0Buy Ratings, 0Hold Ratings, and 0Sell Ratings. DIVISLAB average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
DIVISLAB Stock Forecast FAQ
What is IN:DIVISLAB’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:DIVISLAB’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:DIVISLAB, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Divi's Laboratories Limited a Buy, Sell or Hold?
Currently, no data Available
What is Divi's Laboratories Limited’s share price target?
Currently, no data Available
What do analysts say about Divi's Laboratories Limited?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of Divi's Laboratories Limited?
To buy shares of IN:DIVISLAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.